Traditional Chinese medicine preparation for preventing chronic hepatitis B YMDD (tyrosine, methionine, d-aspartic acid, d-aspartic acid) mutation

Abstract

The invention discloses a traditional Chinese medicine preparation for preventing chronic hepatitis B YMDD (tyrosine, methionine, d-aspartic acid, d-aspartic acid) mutation. According to traditional Chinese medicine, the etiology and pathogenesis of chronic hepatitis B are complicated, a patient is infected with damp-heat epidemic toxin, so that damp toxin accumulation, qi-stagnation and blood stasis and insufficient anti-pathogenic energy are caused and can cause the chronic hepatitis B. Traditional Chinese medicines comprising herb of sword brake, Chinese knotweed, roots of common sesbania, frangrant ainsliaea herb, all-grass of straightstalk alpine meadowrue, roots of puberulous glochidion herb, multibract raspberry roots, herb of rupestrine dragonhead, roots or leaves of redback christmashush, roots of canna indica and rabdosia serra are selected and decocted to decoction with water. Clinical tests show that the curative effect is remarkable.

Description

technical field

[0001] The invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine preparation for preventing YMDD variation of chronic hepatitis B. Background technique

[0002] After the nucleoside analogue lamivudine binds to HBV polymerase in the form of triphosphorylation in vivo, it competes to inhibit the activity of the polymerase, resulting in the termination of HBV DNA chain synthesis. HBVDNA concentration. However, the tyrosine, methionine, aspartate, and aspartate (YMDD) motifs of the HBV DNA polymerase domain C can be mutated after treatment with lamivudine, resulting in HBV evading the effect of lamivudine and developing resistance. Drug strains, so that the clinical efficacy of lamivudine decreased. It is generally believed that the occurrence of YMDD mutations is more common after half a year of treatment with lamivudine, and the YMDD mutation rate is about 25% after 52 weeks of treatment. However, r...